Income statement
CAD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1M | 2M | 15M | 21M | 0 |
| Gross Profit | 893K | 857K | 3M | -324K | 0 |
| Operating Income | -2M | -4M | -4M | -3M | 0 |
| EBITDA | -2M | -3M | -3M | -3M | -72K |
| Net Income | -4M | -3M | -5M | -9M | -72K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.002
+0.00% today
1Y Change
+122.22%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Justera Health Ltd. (SCRSF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 122.2% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of -25.8%, EPS growth of -1.3%, a dividend yield of 0.0%. What stands out right now is revenue -25.8%, EPS -1.3%, free cash flow +139.5% with operating margin -172.2% and ROIC 69.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SCRSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCRSF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCRSF Max Drawdown
-33.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCRSF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$72.3K
+99.2% YoY
Free Cash Flow
-$18.5K
+98.6% YoY
Revenue Growth
-25.8%
EPS Growth
-1.3%
Gross Margin
62.9%
Net Margin
-296.6%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1M | 2M | 15M | 21M | 0 |
| Gross Profit | 893K | 857K | 3M | -324K | 0 |
| Operating Income | -2M | -4M | -4M | -3M | 0 |
| EBITDA | -2M | -3M | -3M | -3M | -72K |
| Net Income | -4M | -3M | -5M | -9M | -72K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54K | 95K | 437K | 209K | 32 |
| Total Assets | 2M | 2M | 5M | 5M | 32 |
| Total Liabilities | 5M | 2M | 4M | 4M | 179K |
| Shareholder Equity | -4M | -450K | 1M | 852K | -179K |
| Total Debt | 165K | 334K | 121K | 160K | 132K |
| Net Debt | 111K | 240K | -317K | -49K | 132K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
19K
+96.3% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
19K
+98.6% YoY
Key ratios
Gross Margin
62.9%
Operating Margin
-172.2%
Net Margin
-296.6%
ROE
201.8%
Debt / Equity
-0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.